Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164179 | 0.91 | POLB (0.67) | POLBKMT2AMEN1CYP2C9ATM | |
| SCHEMBL6162317 | 0.90 | POLB (0.74) | POLBKMT2AMEN1CYP2C9ATM | |
| SCHEMBL6163364 | 0.85 | CYP2C9 (0.74) | POLBKMT2AMEN1CYP2C9RAB9A | |
| SCHEMBL6164125 | 0.83 | POLB (0.65) | POLBKMT2AMEN1CYP2C9ATM | |
| SCHEMBL6164543 | 0.83 | POLB (0.69) | POLBKMT2AMEN1CYP2C9ATM | |
| SCHEMBL6165140 | 0.81 | HCRTR1 (0.49) | POLBKMT2AMEN1RAB9ATDP1 | |
| SCHEMBL6164043 | 0.81 | HCRTR1 (0.49) | POLBKMT2AMEN1RAB9ATDP1 | |
| SCHEMBL6165232 | 0.81 | HCRTR1 (0.49) | POLBKMT2AMEN1RAB9ATDP1 | |
| SCHEMBL10757593 | 0.80 | CYP2C9 (0.83) | POLBKMT2AMEN1CYP2C9RAB9A | |
| SCHEMBL6162031 | 0.80 | POLB (1.00) | POLBKMT2AMEN1CYP2C9ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337523-B1 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORP (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040048867-A1 | 2,4-Substituted pyridine derivatives | NEUROGEN CORPORATION | 2004-03-11 | — | — | US | claimed |
| US-20020161008-A1 | 2,4-Substituted pyridine derivatives | NEUROGEN CORPORATION | 2002-10-31 | — | — | US | claimed |
| US-6559163-B2 | Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression | NEUROGEN CORPORATION | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161008-A1 | 2,4-Substituted pyridine derivatives | GABARAP, GABRB1, GABARAPL1 | POLB 1324/4885KMT2A 968/4885MEN1 4655/4885 |
| US-20040048867-A1 | 2,4-Substituted pyridine derivatives | GABARAP, GABRB1, GABARAPL1 | POLB 1324/4885KMT2A 968/4885MEN1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.